Leerink Partners analyst David Risinger has reiterated their bullish stance on ORKA stock, giving a Buy rating on September 27.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Risinger has given his Buy rating due to a combination of factors that highlight the potential of Oruka Therapeutics’ ORKA-002. The recent mixed results from MLTX’s Phase 3 trials for sonelokimab, an anti-IL-17A/F nanobody, in treating hidradenitis suppurativa (HS) have positioned ORKA-002 as a promising alternative. ORKA-002 shares a mechanism of action similar to UCB’s Bimzelx, but with the potential for more convenient dosing, which could offer a significant advantage in the market.
Furthermore, Oruka Therapeutics is on schedule to release interim Phase 1 data for ORKA-002 by the end of the year and plans to initiate Phase 2 trials in psoriasis in the first half of 2026, followed by studies in HS. The preclinical data for ORKA-002 suggests a competitive efficacy profile, and its potential for less frequent dosing compared to Bimzelx could enhance its appeal. These factors collectively underpin Risinger’s optimistic outlook and Buy rating for Oruka Therapeutics.
In another report released on September 27, LifeSci Capital also maintained a Buy rating on the stock with a $41.00 price target.